Heart failure with preserved ejection fraction (HFpEF) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that HFpEF accounts for nearly half of all CHF cases, there are no therapies with a proven benefit approved for this patient population. Physicians usually prescribe ACE inhibitors or AIIRAs, beta blockers, and diuretics with the focus to relieve symptoms and manage comorbidities such as hypertension, T2D, or CAD. Unlike HFrEF, calcium-channel blockers can be used in this patient population. The HFpEF Treatment Algorithm provides insight into prescribing patterns of a CHF subpopulation that offers huge commercial opportunity to a drug that is evaluated specifically in this population.